Drug Trial Radar · NCT05957978
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Mar 29, 2024
Primary completion
Jun 27, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Jul 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 44 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, phase II, single-centre study, with one LXE408 regimen and one calibrator arm with the standard of care SSG combined with PM, to be conducted in male and female adult (≥18 years and \<45 years) patients with confirmed primary visceral leishmaniasis in Ethiopia.
Conditions
- Primary Visceral Leishmaniasis
Interventions
LXE408Drug
Film-coated tablets
sodium stibogluconateDrug
Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.
ParomomycinDrug
Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients treated with LXE408 with initial cure at Day 28Time frame: Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Gondar
Gonder, Ethiopia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.